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regulate oligodendrocyte progenitor cell
(OPC) migration at the motor exit point
transition zone. Loss of bothmechanisms
results in ectopic OPCs in the peripheral
nervous system.
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During development, oligodendrocyte progenitor
cells (OPCs) migrate extensively throughout the spi-
nal cord.However, theirmigration is restricted at tran-
sition zones (TZs). At these specialized locations,
unique glial cells in both zebrafish and mice play a
role in preventing peripheral OPC migration, but the
mechanisms of this regulation are not understood.
To elucidate the mechanisms that mediate OPC
segregation at motor exit point (MEP) TZs, we per-
formed an unbiased small-molecule screen. Using
chemical screening and in vivo imaging, we discov-
ered that inhibition of A2a adenosine receptors
(ARs) causes ectopic OPCmigration out of the spinal
cord. We provide in vivo evidence that neuromodu-
lation, partially mediated by adenosine, influences
OPC migration specifically at the MEP TZ. This work
opens exciting possibilities for understanding how
OPCs reach their final destinations during develop-
ment and identifies mechanisms that could promote
their migration in disease.
INTRODUCTION
Oligodendrocyte progenitor cells (OPC) are migratory, prolifera-
tive cells with multiple functions in CNS development and dis-
ease (Bergles and Richardson, 2015; Emery and Lu, 2015;
Zuchero and Barres, 2015). These progenitors differentiate into
oligodendrocytes (OLs), which ensheath axons in an insulating
layer of myelin that is essential for saltatory conduction (Simons
and Nave, 2015). During gliogenesis, OPCs are specified from
precursor domains within the brain and spinal cord, but they
migrate extensively to become distributed throughout the entire
CNS (Miller, 2002; Rowitch, 2004). In the spinal cord, most OPCs
are specified from ventral motor neuron progenitor (pMN) pre-
cursors that also give rise to motor neurons during neurogenesis
(Richardson et al., 2000). These motor neurons extend axons
ventrally toward the motor exit point (MEP) transition zone (TZ)This is an open access article under the CC BY-Nand cross into the peripheral nervous system (PNS), where
they ultimately innervate targets including skeletal muscle (Bo-
nanomi and Pfaff, 2010; Lewis and Eisen, 2003). As OPCs
disperse from the pMN domain to populate the spinal cord, a
subset transiently extends membrane processes through the
MEP TZ into the PNS (Fraher and Kaar, 1984; Smith et al.,
2014). However, under normal physiological conditions, these
processes retract back into the spinal cord, and OPC bodies
are restricted from migrating onto peripheral nerves.
The mechanisms allowing selective migration of motor axons
and other glial populations, but not OPCs, through the MEP TZ
are not understood. Recently, work from our lab and others
has shown that OPCs are capable of migrating into the PNS in
zebrafish and mouse mutants with PNS defects, and peripheral
OPCs have even been described in human peripheral neuropa-
thy patients (Coulpier et al., 2010; Fro¨b et al., 2012; Kucenas
et al., 2009; Smith et al., 2014). On the basis of these studies,
we hypothesize that active regulation of OPC migration restricts
them to the CNS.
Although the molecular mechanisms that mediate OPC re-
striction to the CNS are unknown, previous work from our lab
identified a population of CNS-derived peripheral glial cells
called MEP glia, which are essential for preventing OPC migra-
tion onto spinal motor nerves (Smith et al., 2014). A similar pop-
ulation known as boundary cap (BC) cells, located at TZs, exists
in mice and is hypothesized to regulate OPC migration at these
positions as well (Coulpier et al., 2010; Fro¨b et al., 2012).
In order to identify additional mechanisms regulating OPC
migration at the MEP TZ, we performed an unbiased chemical
screen that identified ten small molecules that resulted in
peripherally located OPCs. We focused further testing on one
of these compounds, an adenosine receptor (AR) antagonist,
because adenosine is a well-known modulator of neuronal ac-
tivity, and neuronal activity has been implicated in regulating
OPC differentiation, proliferation, and migration (Chen et al.,
2018; Etxeberria et al., 2016; Gibson et al., 2014; Hines et al.,
2015; Ka´rado´ttir and Attwell, 2007; Mensch et al., 2015; Mitew
et al., 2018; Nagy et al., 2017; Stevens et al., 2002). Therefore,
we hypothesized that adenosinergic regulation of neuronal ac-
tivity may be involved in restricting OPC migration at the MEP
TZ. Here, we report that adenosine signaling through A2aCell Reports 27, 115–128, April 2, 2019 ª 2019 The Author(s). 115
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Small-Molecule Screen Identifies
Compounds that Disrupt OPC Migration at
the MEP TZ
(A) Schematic of a transverse view of the MEP TZ.
MEP glia (MEPg; green) prevent OPC (yellow) exit
from the spinal cord (gray). OPC processes (arrow)
contact MEP glia but are repelled. Without MEP
glia, OPCs migrate onto peripheral nerves.
(B) Low-magnification images showing lateral
views of negative (top) and positive (bottom) con-
trols at 3 dpf in olig2:dsred larvae. Peripheral olig2+
cells are denoted with yellow arrowheads.
(C) Images of control and validated hits in 3 dpf
olig2:dsred larvae showing ectopic OPCs (arrow-
head) along spinal motor nerves.
(D) Mean ± SEM of peripheral OPC count for larvae
injected with injection buffer (control) or TeNT
mRNA at 3 dpf. p = 0.0013; n = 14 control, n = 23
TeNT.
Scale bars, 100 mM in (B) and 20 mM in (C).ARs functions to regulate OPC migration at MEP TZs during
development.
RESULTS
Identification of Mechanisms that Induce Ectopic OPC
Migration through the MEP TZ
Glial cells that establish a barrier to OPC migration across the
MEP TZ exist in mice and fish (Coulpier et al., 2010; Fro¨b et al.,
2012; Smith et al., 2014). In zebrafish, during development,
ventral OPCs within the spinal cord extend membrane pro-
cesses through the MEP TZ and contact MEP glia in the PNS
(Figure 1A). When this occurs, the OPC is immediately repelled
and retracts its process. WhenMEP glia are absent, OPCs freely
migrate through the MEP TZ and onto peripheral motor nerves
(Figure 1A) (Morris et al., 2017; Smith et al., 2014). However,
the signals restricting OPC migration at the MEP are unknown.
Therefore, to identify molecular mechanisms regulating OPC
migration at the MEP TZ, we conducted an unbiased screen of
small molecules to identify signaling cascades involved in OPC
segregation to the CNS.
To conduct our screen, we treated 24 h post-fertilization (hpf)
olig2:dsred embryos with compounds from the Library of Phar-
macologically Active Compounds (LOPAC1280). In our primary
screen, embryos were treated with 10 mM of a compound from
the library, 1% DMSO as a negative control, or 4 mM AG1478
as a positive control (Figure 1B). The positive control AG1478 in-
hibits Erbb3 signaling and phenocopies the erbb3b mutation
(Lyons et al., 2005). Previously, we demonstrated that erbb3b
mutants have peripherally located OPCs because they lack
MEP glia (Morris et al., 2017; Smith et al., 2014). A pilot experi-116 Cell Reports 27, 115–128, April 2, 2019ment confirmed that treatment with 4 mM
AG1478 from 24 hpf to 3 days post-fertil-
ization (dpf) caused robust peripheral
OPC migration, whereas 1% DMSO did
not (Figure 1B). For the rest of our screen,
we analyzed larvae at 3 dpf for the pres-ence of olig2+ cell bodies in the periphery (Figure 1C). We iden-
tified 197 ‘‘hits’’ in our primary screen, and these compounds
were retested in a secondary screen, and any that resulted in
peripheral olig2+ cells was considered a validated hit (Figure 1C).
This protocol resulted in 10 total hits, many of which are involved
in neurotransmission and/or modulation of neuronal activity
(Table 1).
Because several of the compounds from our screen are neuro-
modulators, we next tested whether a non-pharmacological
method of inhibiting neuronal activity would result in peripheral
OPCmigration. To do this, we inhibited all vesicular release using
tetanus toxin light chain (TeNT) (Yu et al., 2004). Previous studies
demonstrate that injections of TeNT mRNA effectively inhibit ve-
sicular release and lead to significant paralysis of zebrafish
larvae (Fontenas et al., 2016; Mensch et al., 2015). When we
injected olig2:dsred embryos at the one-cell stage with 1 to 2
nL of 200 ng/mL TeNTmRNA, we confirmed that neuronal activity
was indeed inhibited, as larvae were paralyzed at 2 dpf (n = 54)
and 3 dpf (n = 52) (Figures S1A and S1B; 2 dpf, p < 0.0001; 3
dpf, p < 0.0001). Consistent with our hypothesis, silencing neu-
rons using TeNT resulted in significant numbers of OPC bodies
in the periphery (Figure 1D; n = 14 larvae [control], n = 23 larvae
[TeNT]; p = 0.0013). From these results, we hypothesize that neu-
ral activity influences OPC migration at MEP TZs.
A2a ARs Influence OPC Migration at the MEP TZ
One compound we identified, CGS-15943, is a highly potent,
non-selective AR antagonist (Ongini et al., 1999). Adenosine is
a well-known modulator of neuronal activity and can either in-
crease or decrease neuronal firing by binding to different ARs
(Sebasti~ao andRibeiro, 2015). Because adenosine canmodulate
Table 1. Validated Hits from Screen Using LOPAC1280
Drug Name Description
CGS-15943 highly potent, non-selective
adenosine receptor antagonist
1-Phenyl-3-(thiazolyl)-2-
thiourea
dopamine b-hydroxylase inhibitor
Acetylthiocholine chloride nicotinic acetylcholine receptor
agonist
Brefeldin A from Penicillium
brefeldianum
causes collapse of Golgi
apparatus, blocking exocytosis
N-phenylanthranilic acid Cl channel blocker
Salmeterol xinafoate selective b2 adrenergic receptor
agonist
I-OMe-tyrphostin AG 538 insulin growth factor I (IGF-1)
receptor inhibitor
L-canavanine sulfate selective inhibitor of inducible
nitric oxide synthase (iNOS)
Clofibrate peroxisome proliferator-activated
receptor-a (PPARa) agonist
Wortmannin from Penicillium
funiculosum
selective phosphatidylinositol
3-kinase (PI3-K) inhibitorneuronal activity and purinergic signaling has been implicated in
OL differentiation and migration (Agresti et al., 2005a, 2005b;
Coppi et al., 2013, 2015; Dennis et al., 2012; Othman et al.,
2003; Stevens et al., 2002), we focused our experiments on
this hit from our screen.
We first confirmed that CGS-15943 caused peripheral OPC
migration through the MEP TZ by performing in vivo, time-lapse
imaging. In order to distinguish OPCs from motor neurons, we
used embryos expressing olig2:dsred and sox10:eos, where
OPCs are Eos+ and DsRed+ (yellow). We treated these embryos
with 10 mM of CGS-15943 from 24 hpf to 3 dpf and imaged three
larvae (ten nerves total) from 55 hpf to 3 dpf. In these time-lapse
movies, we observed sox10+/olig2+ cells with highly dynamic
membrane processes at the MEP TZ (Figure 2A). In nine of ten
nerves (90%) imaged, OPCs extended highly dynamic mem-
brane processes through the MEP TZ. In six of ten nerves
(60%), OPC bodies squeezed through this opening andmigrated
onto peripheral spinal motor nerves during imaging (Figure 2A;
Video S1). This migration most often occurred between 60 and
72 hpf, although we also observed OPCs already present on
the nerve before 60 hpf (three of ten nerves [30%]). Interestingly,
we never observed any olig2+/sox10 motor neurons in the pe-
riphery in these time-lapse movies (zero of ten nerves [0%]),
indicating that adenosine signaling is involved in restricting
OPCs, but not motor neurons, to the spinal cord. This is consis-
tent with evidence from our lab and others demonstrating that
distinct mechanisms regulate segregation of glia and neurons
at the MEP TZ (Fro¨b et al., 2012; Kucenas et al., 2009).
We next sought to determine which AR subtype was involved
in preventing peripheral OPC migration. To do this, we treated
embryos expressing olig2:dsred from 24 hpf to 3 dpf with varying
concentrations of selective antagonists for each of the four
AR subtypes: A1 (8-cyclopentyltheophylline [CPT]), A2a (SCH-
58261), A2b (MRS-1754), and A3 (MRS-1191), as well as thegeneral AR antagonist CGS-15943 (Jiang et al., 1996; Ongini
et al., 1999; Searl and Silinsky, 2012; Wei et al., 2013). We
analyzed drug-treated larvae at 3 dpf and quantified the number
of peripheral olig2+OPCs. As expected, CGS-15943 caused sig-
nificant peripheral OPC migration (Figure S2A; p < 0.01). The
selective A2a AR antagonist SCH-58261 also resulted in signifi-
cant numbers of peripheral olig2+ OPC bodies and membrane
processes (Figures 2B and 2C; p < 0.01 for 10 mM SCH-58261
compared with DMSO). In contrast, we did not observe periph-
eral OPCs following treatment with selective antagonists for
any of the other AR subtypes (Figures S2B–S2D). From these
data, we conclude that A2a ARs are involved in regulating OPC
migration at MEP TZs.
We sought to further confirm the selectivity of SCH-58261 ac-
tivity to A2a ARs with competitive binding experiments. If SCH-
58261 selectively antagonizes the A2a AR, we hypothesized
that co-administering an A2a agonist would rescue the periph-
eral migration phenotype caused by SCH-58261. To test this,
we treated 24 hpf olig2:dsred embryos with 10 mM SCH-58261
combined with 5 mM adenosine or 2.5 mM of the A2a selective
agonist CGS-21680 and quantified the number of peripheral
OPCs at 3 dpf (Jarvis and Williams, 1989). Both adenosine and
CGS-21680 significantly decreased the number of peripheral
OPCs when co-administered with SCH-58261 (Figure 2D; p <
0.05, CGS-21680; p < 0.01, adenosine compared with SCH-
58261 alone; n = 30 larvae). These results support the conclusion
that SCH-58261 selectively antagonizes A2a ARs to induce
ectopic OPC migration. To confirm that adenosine or CGS-
21680 treatment alone did not interfere with normal OPC devel-
opment or migration, we imaged olig2:dsred zebrafish larvae
at 3 dpf following treatment with adenosine, CGS-21680, or
DMSO from 24 hpf to 3 dpf and quantified dorsal spinal cord
olig2+ OPCs in a four-somite region. In these studies, we did
not observe any differences among treatments (Figure S2E;
p = 0.23; adenosine, n = 4 larvae; CGS-21680, n = 9 larvae;
DMSO, n = 11 larvae).
In our initial screen, our treatment protocol spanned from 24
hpf to 3 dpf, encompassing OPC specification, proliferation,
and migration (Kirby et al., 2006; Kucenas et al., 2008a; Park
et al., 2002). Therefore, we sought to narrow the treatment win-
dow. To do this, we treated olig2:dsred embryos with 10 mM
SCH-58261 during various time windows and quantified the
number of peripheral OPCs at 3 dpf. We found that exposure
to SCH-58261 beginning later than 54 hpf or ending earlier
than 54 hpf did not result in any peripheral OPC migration (Fig-
ures 2E and S2F–S2H; n = 7–12 larvae). At this stage, OPCs
are migrating throughout the spinal cord and we previously
observedOPCs extendingmembrane processes into the periph-
ery and contacting MEP glia at this developmental stage (Kirby
et al., 2006; Smith et al., 2014). From these experiments, we
conclude that adenosine signaling functions when OPCs are
migrating.
A2a AR Antagonists Do Not Disrupt Spinal Motor Nerve
Development
Previously, we demonstrated that loss of MEP glia results in OPC
migration into the periphery (Morris et al., 2017; Smith et al.,
2014). We therefore sought to determine whether antagonizingCell Reports 27, 115–128, April 2, 2019 117
Figure 2. A2a AR Antagonist Causes OPC
Migration through the MEP TZ
(A) Frames captured from a 15 h time-lapse movie
of a sox10:eos;olig2:dsred larva treated with CGS-
15943 from 24 hpf to 3 dpf and imaged from 57 to
72 hpf; 00 is 58 hpf. The black asterisk marks OPC
body. Arrowheads mark OPC leading process.
(B) Dose-response curve of the number of pe-
ripheral OPCs for fish treated from 24 hpf to 3 dpf
with SCH-58261. Mean ± SEM, n = 10 larvae per
dose; **p < 0.01 and ***p < 0.0001.
(C) Percentage of nerves at 3 dpf that have ectopic
OPC processes and/or cell bodies. n = 60 DMSO,
n = 98 SCH-58261; p < 0.01.
(D) Mean ± SEM of peripheral OPCs in olig2:dsred
larvae treated with 10 mM SCH-58261 alone or in
combination with 2.5 mM CGS-21680 or 5 mM
adenosine from 36 hpf to 3 dpf. n = 30 fish per
treatment; *p < 0.05 and **p < 0.01.
(E) Peripheral OPC counts for larvae treated with
10 mM SCH-58261 during distinct time periods.
Green bars indicate mean peripheral OPC counts
significantly above DMSO control (p < 0.05). Red
bars indicate mean peripheral OPC counts not
significantlydifferent thanDMSO (p>0.05). n=9–12
larvae per condition. Scale bar, 20 mM.the A2a AR led to ectopic OPCmigration by perturbing MEP glial
development. MEP glia can be identified by the co-expression of
sox10:eos and olig2:dsred, as well as expression of wnt inhibi-
tory factor 1 (wif1) (Smith et al., 2014). To determine if MEP glia
were present in larvae treated with the A2a AR antagonist, we
quantified the percentage of motor nerves with sox10+/olig2+
MEP glia at the MEP TZ and observed no differences among
larvae treated from 36 hpf to 3 dpf with 1.25 mM CGS-15943
(n = 6 larvae), 10 mM SCH-58261 (n = 9 larvae), or DMSO (n = 5
larvae) (Figures 3A and 3B; p = 0.14, ten nerves analyzed per
larvae). We also observed wif1+ MEP glia at 54 hpf in larvae
treated with 1.25 mMCGS-15943 from 36 to 54 hpf (Figure S3A).
From these data, we conclude that A2a AR antagonism does not
affect MEP glial development.
To determine whether glial migration was generally disrupted
at the MEP TZ in larvae treated with the A2a AR antagonist, we
assayed the migration of perineurial glia (PG). These cells origi-
nate in the ventral spinal cord, exit the CNS via the MEP TZ,
and migrate along motor nerves to form the perineurium (Clark
et al., 2014; Kucenas et al., 2008b). If the A2a AR antagonist non-118 Cell Reports 27, 115–128, April 2, 2019selectively disrupted cell migration at the
MEP TZ, we hypothesized that we would
observe altered extension of PG along
spinal motor nerves. To investigate this,
we measured extension of PG from the
spinal cord along motor nerves in 55 hpf
nkx2.2a:megfp;olig2:dsred larvae treated
from 36 to 55 hpf with 1.25 mm CGS-
15943. In these studies, we found no dif-
ference in PG extension between DMSO
andCGS-15943-treated larvae, indicating
that A2a AR signaling does not generallyaffect glial migration at the MEP TZ (Figure 3C; p = 0.28; DMSO
22.27 ± 0.88 mm [mean ± SEM], n = 6 larvae, ten nerves analyzed
per larva; CGS-15943 24.94 ± 1.75 mm [mean ± SEM], n = 10
larvae, ten nerves analyzed per larva).
Finally, we assessed Schwann cell (SC) development along
spinal motor nerve roots. Using 3 dpf sox10:eos larvae, we
quantified the number of Eos+ cells between the MEP TZ and
horizontal myoseptum. In this experiment, we observed that
the number of Eos+ cells per nerve was not significantly different
between animals treated from 36 hpf to 3 dpf with DMSO or
SCH-58261 (p = 0.08), and we saw no difference in the number
of Eos+ glia when we compared counts between nerves popu-
lated with ectopic OPCs and those without (Figure 3D). We
also performed time-lapse imaging in sox10:nls-eos larvae
starting at 36 hpf and observed that migration, proliferation,
and apoptosis were indistinguishable between SCH-58261-
treated and DMSO-treated larvae (Figures 3E–3G). Finally, we
confirmed that SCs produced MBP+ myelin sheaths at 5 dpf in
both DMSO- and SCH-58261-treated larvae (Figures S3B).
From these experiments, we conclude that A2a AR antagonism
Figure 3. A2a AR Antagonism Does Not
Affect Spinal Motor Nerve Development
(A) Motor nerve in a 3 dpf olig2:dsred;sox10:eos
larvae treated with SCH-58261 from 36 hpf to 3
dpf. Red asterisks mark sox10+/olig2+ MEP glia at
the MEP TZ. Black pound signs denote sox10+/
olig2 dorsal root ganglia.
(B) Mean ± SEM of the percentage of nerves per
larva at 3 dpf with sox10+/olig2+ MEP glia after
treatment from 36 hpf to 3 dpf with DMSO (n = 5),
CGS-15943 (n = 6), or SCH-58261 (n = 9). Ten
nerves were quantified per larva. p = 0.14.
(C) Fifty-five hours post-fertilization nkx2.2a:
megfp;olig2:dsred larvae treated with DMSO or
CGS-15943 from 36 to 55 hpf showing PG exten-
sion (arrowheads) on the nerve.
(D) Quantification of Eos+ cells per nerve at 3 dpf in
DMSO and SCH-58261-treated larvae. Mean ±
SEM for DMSO (n = 6 fish) and SCH-58261 (n = 10
fish). Ten nerves per fish. p = 0.39.
(E) Frames captured from a 20 h time-lapse video
starting at 36 hpf in sox10:nls-eos embryos treated
with DMSO or SCH-58261. The spinal cord is de-
noted by a dashed line. SCs divide (yellow arrow-
heads) along the nerves in both treatments.
(F) Quantification of SC proliferation during these
time lapses. Mean ± SEM for DMSO (n = 6 fish,
21 nerves) and SCH-58261 (n = 6 fish, 23 nerves).
p = 0.35.
(G) Quantification of SC death during these time-
lapse movies. Mean ± SEM for DMSO (n = 6 fish,
21 nerves) and SCH-58261 (n = 6 fish, 23 nerves).
p = 0.20. Scale bars, 20 mM.does not cause peripheral OPC migration by disrupting motor
nerve development.
The A2ab AR Influences OPC Migration at MEP TZs
Zebrafish have two orthologous A2a ARs, A2aa and A2ab,
which are encoded by adora2aa and adora2ab, respectively
(Boehmler et al., 2009). We used Clustal Omega to compare
the zebrafish A2aa, A2ab, and the human A2A AR protein se-
quences (Goujon et al., 2010; Sievers et al., 2011). Zebrafish
A2aa and A2ab ARs have 55% and 52% identical amino acids
to human A2A AR (Figure S4). However, most of this variability
is in the C-terminal cytoplasmic tail, which mediates interac-
tions with other proteins and not ligand binding (Keuerleber
et al., 2010). The ligand binding domains of zebrafish A2aa
and A2ab ARs are 72% (21 of 29) conserved with human A2A
AR, and A2aa and A2ab ARs have 76% (22 of 29) conserved
amino acids with each other in this domain, so they likely
have similar ligand affinities (Figure S4). However, adora2aa
and adora2ab have distinct expression patterns, so we hypoth-Cesized that they may have unique func-
tions in nervous system development
(Boehmler et al., 2009).
To determine if A2aa and/or A2ab ARs
were required to prevent peripheral OPC
migration, we created genetic mutants
for adora2aa and adora2ab. We createdgermline mutations in adora2aa using transcription activator-
like effector nuclease (TALEN) targeted mutagenesis (Boch
et al., 2009; Moscou and Bogdanove, 2009). Adora2aact845 is a
7 bp deletion within exon 3, which causes a frameshift and early
stop codon, and this results in a severely truncated protein
sequence (FigureS5A). ThemutatedA2aaARprotein lacks trans-
membrane domains 6 and 7, which contain conserved ligand
binding residues (de Lera Ruiz et al., 2014). It also lacks the entire
C-terminal cytoplasmic tail, which mediates interaction with G
proteins andprotects the receptor fromubiquitination anddegra-
dation (Keuerleber et al., 2010). For these reasons, we hypothe-
size that adora2aact845 is a presumptive null. Similar to A2a/
mice, adora2aa/ zebrafish mutants are homozygous viable,
produce viable offspring, and donot showanymorphological de-
fects compared with wild-type (WT) siblings at all stages investi-
gated (Figure S5B) (Chen et al., 1999).
We also created germline mutations in adora2ab using
CRISPR/Cas9 (Hwang et al., 2013). We designed a single guide
RNA (sgRNA) targeting adora2ab exon 2, just downstream of theell Reports 27, 115–128, April 2, 2019 119
Figure 4. A2ab ARs Influence OPC Migra-
tion at the MEP TZ
(A) adora2ab WT and germline CRISPR mutant
DNA sequences. sgRNA target and PAM site
(underlined) are shown on WT sequence. Red
letters or dashes indicate insertions or deletions.
(B) Diagram of A2ab protein with locations of early
stops caused by adora2abuva6, adora2abuva7, and
adora2abuva9.
(C) Bright-field images of WT and adora2ab/
siblings at 3 and 5 dpf.
(D) Mean ± SEM of peripheral OPCs per fish for
olig2:dsred;adora2aa/ and WT larvae treated
with water, DMSO, or 10 mM SCH-58261 from 36
hpf to 3 dpf. n = 12 fish; p < 0.0001 for treatment,
p = 0.53 for genotype, p = 0.93 for interaction of
treatment and genotype.
(E) Mean ± SEM of peripheral OPCs per fish for
olig2:dsred;adora2ab/, adora2ab+/, and WT
larvae. p = 0.32; n = 19 adora2ab/, n = 26
adora2ab+/, and n = 16 WT.
(F) Mean ± SEM of dorsally migrated OPCs per
somite at 72 hpf. p = 0.43; n = 6 WT, n = 16 ador-
a2ab+/, n = 9 adora2ab/.
(G) Mean ± SEM of peripheral OPCs per fish for
olig2:dsred;adora2ab/, gpr126/, and WT
larvae injected with injection buffer (control) or
TeNT mRNA. **p = 0.0088 (WT versus WT + TeNT),
**p = 0.0053 (adora2ab+/ versus adora2ab+/ +
TeNT), and ****p < 0.0001 (adora2ab/ versus
adora2ab/ + TeNT); p = 0.99 (WT + TeNT versus
gpr126/ + TeNT) and (WT + TeNT versus ador-
a2ab/ + TeNT). n = 22 WT, n = 22 adora2ab+/,
n = 13 adora2ab/, n = 36 WT + TeNT, n = 32
adora2ab+/ + TeNT, n = 20 adora2ab/ + TeNT,
n = 4 gpr126+/+, and n = 5 gpr126/ + TeNT. Red
asterisks highlight significant comparisons rele-
vant for the experiment.
(H) Mean ± SEM of the percentage of nerves with
peripheral OPC bodies and/or processes at 3 dpf
following TeNT mRNA injections and/or MEP glial
ablation. For each WT or TeNT-injected larva, two
nerves were analyzed with MEP glia ablated, and
two nerves were analyzed with MEP glia intact in
the same larva. n = 5 larvae (uninjected), n = 7
larvae (TeNT). **p = 0.004 for TeNT versus WT,
p < 0.0001 for MEP glia ablated versus MEP glia
present. Scale bar, 0.5 mm.translation start site, and identified three germline frameshift
mutations in the F1 generation (Figure 4A). These alleles include
adora2abuva6, which has a 52 bp deletion in exon 2; adora2a-
buva7, which is a 66 bp insertion within exon 2; and adora2abuva9,
which has a 13 bp deletion in exon 2 (Figure 4B). Because all
three adora2ab mutant alleles lack all conserved ligand binding
domains and C-terminal signaling, we hypothesize that they
are also presumptive null mutations. Similar to adora2aa/
mutant larvae, adora2ab/ mutant larvae do not show any
morphological defects compared with WT siblings at all stages
investigated (Figure 4C).
To determine if adora2aa mediated OPC restriction from the
PNS, we quantified the number of peripheral OPCs at 3 dpf in
olig2:dsred;adora2aa mutant larvae. In these mutants, we did
not observe significant numbers of peripheral OPCs compared120 Cell Reports 27, 115–128, April 2, 2019with WT and heterozygous siblings (Figure S5C; p = 0.69; n = 7
adora2aa+/+, n = 20 adora2aa+/, n = 26 adora2aa/). To deter-
mine if bothA2aparalogs inzebrafishwere involved insegregating
OPCs to the spinal cord, we treated olig2:dsred;adora2aa/
larvae, which still have functional A2ab ARs, with the A2a AR
antagonist SCH-58261 at 36 hpf. At 3 dpf, we did not observe
peripherally migrated OPCs in WT or adora2aa/ larvae treated
with DMSO (Figure 4D; n = 12). However, when WT or adora2aa
mutant larvae were treated with SCH-58261 from 36 hpf to 3
dpf, we observed peripheral OPCs in both genotypes (Figure 4D;
n = 12). Two-way ANOVA analysis showed a significant effect of
drug treatment (p < 0.0001) but not for genotype (p = 0.53) or
the interaction between treatment and genotype (p = 0.93). In
other words, both WT and adora2aa mutant larvae have the
same number of peripherally migrated OPCs when treated with
the A2a AR antagonist. These results led us to hypothesize that
A2abmay be involved inOPCmigration at theMEPTZ. Therefore,
we quantified peripheral OPCs in 3 dpf olig2:egfp;adora2ab/
larvae. We did not observe any peripheral OPC migration in WT
larvae, but we did observe variable numbers of olig2+OPCs along
peripheral motor nerves in adora2ab+/ and adora2ab/ larvae
(Figure 4E; p = 0.32; n = 16 WT, n = 26 adora2ab+/, n = 19
adora2ab/). However, the phenotype of peripheral OPCmigra-
tion in adora2ab/ larvae was not as robust as in larvae treated
with the A2a antagonist SCH-58261 and was not significantly
different from WT siblings. We discuss this in greater detail later.
To ruleout ageneral defect inOPCmigrationcausedbyamutation
in adora2ab, we time-lapse-imaged olig2:egfp;adora2abmutants
and their siblings from 55 to 72 hpf and quantified the number of
dorsally migrated OPCs in the spinal cord. In these movies, we
did not observe any significant difference inOPC activity between
adora2abmutant larvaeand siblings (Figure 4F; p=0.43; n =6WT,
n = 16 adora2ab+/, n = 9 adora2ab/).
Asan independent testof the roleofA2abARs inOPCrestriction
to the spinal cord, we performed genetic knockdown of adora2aa
and adora2abusingmorpholinooligonucleotides (MOs).Whenwe
quantifiedperipherallymigratedOPCs in larvae injectedwithMOs
at the one-cell stage, adora2abMO1 morphants (n = 42), but not
adora2aaMO1morphants (n=65), had significantlymoreperipheral
OPCs at 3 dpf compared with uninjected (n = 42) and phenol red-
injected (n = 11) larvae (p < 0.0001) (Figures S6A and S6C). This
result is consistent with our finding that adora2aa/ larvae do
not have peripherally migrated OPCs (Figure S5C). Similarly, we
observed ectopic peripheral OPCs only in adora2aa/ larvae in-
jected with adora2abMO (n = 84) but not in control-injected (n =
30) adora2aa/ larvae (Figure S6B; p < 0.0001). To directly rule
out the possibility that the phenotype we see in adora2ab mor-
phants is due to an off-target effect of the MO, we injected WT
and adora2ab mutants with 1 ng/nL adora2ab MO at the one-
cell stage. We quantified the number of peripheral OPCs and
observed that the effect of the MOwas lost in adora2ab/ larvae
and that the number of peripheral OPCs was comparable with
that in uninjected adora2ab mutant larvae (Figure S6E; p = 0.03
[adora2ab MO-injected adora2ab+/+ versus adora2ab MO-in-
jected adora2ab/]; n = 20 adora2ab+/+, n = 13 adora2ab/).
In these studies, we discovered a difference between our
adora2ab MO-injected and adora2ab/ embryos. The genetic
perturbation of adenosine signaling throughA2ab loss of function
in our CRISPR mutants could trigger genetic compensation,
leading to a subsequent rebalancing of neuronal activity, and
mask the role of A2ab ARs in OPC migration at the MEP TZ (El-
Brolosy et al., 2018; Rossi et al., 2015). Because of the high
homology between the paralogs adora2aa and adora2ab, we
hypothesized that A2aa could compensate for A2ab to mediate
adenosine signaling in adora2ab/ larvae. To test this hy-
pothesis, we examined peripheral OPC migration in olig2:dsred;
adora2aa;adora2ab double-mutant larvae at 3 dpf. In these
larvae, we did not see any significant change in the number of
peripherally migrated OPCs (Figure S6D; p = 0.75). In support
of this, we performed qRT-PCR at 72 hpf and did not detect up-
regulation of adora2aa mRNA expression in adora2ab/ larvae
(data not shown). We conclude from these experiments that the
compensatory mechanisms triggered by mutations in adora2abdo not function through adora2aa but likely through other mech-
anisms regulating neuronal activity.
Because A2a ARs are excitatory G protein-coupled recep-
tors that are known to function in neuromodulation, we hypoth-
esized that a plausible compensatory mechanism at play could
involve the enhancement of other mechanisms that drive neural
activity. Therefore, we asked whether silencing neurons via
inhibition of vesicular release would attenuate these compen-
satory mechanisms and consequently elicit enhanced OPC
migration in adora2ab mutant larvae. To test this hypothesis,
we injected olig2:dsred;adora2ab mutant embryos at the one-
cell stage with 1–2 nL of 200 ng/mL TeNT mRNA to block vesic-
ular release. Consistent with our hypothesis, we observed a
significant increase in the number of peripheral OPCs in ador-
a2ab/ mutant larvae compared with WT when neuronal activ-
ity was inhibited (Figure 4G; n = 22 WT, n = 22 adora2ab+/, n =
13 adora2ab/, n = 36 WT + TeNT, n = 32 adora2ab+/ +
TeNT, n = 20 adora2ab/ + TeNT; p < 0.0001, WT + TeNT
versus adora2ab/ + TeNT; p < 0.0001, adora2ab/ versus
adora2ab/ + TeNT). As a way to demonstrate that A2ab is
specifically enhancing the TeNT phenotype, we injected TeNT
mRNA into zebrafish embryos harboring a mutation in G protein
coupled receptor 126 (gpr126) at the one-cell stage. In these
mutant larvae, we never see ectopic OPCs under normal con-
ditions, and gpr126 does not play a role in neuromodulation.
However, we would expect injection of TeNT mRNA to result
in the ectopic migration of OPCs. We therefore quantified the
number of ectopic OPCs in TeNT-injected gpr126 mutant
larvae at 3 dpf and observed that the number of ectopic
OPCs is not significantly different from TeNT-injected WT
larvae (Figure 4G; p = 0.99, WT + TeNT versus gpr126/ +
TeNT; n = 4 gpr126+/+, n = 5 gpr126/ + TeNT). Similar to con-
trol adora2ab/ larvae, TeNT-injected adora2ab/, gpr126/,
and WT larvae do not show any morphological defects at 3 or 5
dpf (Figures S1C and S1D). From these data, we hypothesize
that the enhanced phenotype in adora2ab mutant larvae in-
jected with TeNT mRNA is due to a synergistic inhibition of neu-
ral activity. Therefore, we conclude that neural activity, driven
partially by A2a ARs, leads to OPC restriction at the MEP TZ.
Wenext sought to demonstrate thatOPCmigration atMEPTZs
was regulated by multiple mechanisms involving both neural
modulation and cellular restriction. On the basis of our previous
finding that laser ablation of MEP glia results in ectopic migration
ofOPCs into theperiphery (Smith et al., 2014),weperformedMEP
glial ablation at 55 hpf in sox10:eos larvae that were injected with
1–2 nL of 200 ng/mL TeNT mRNA at the one-cell stage. In these
larvae,weobservedasignificant increase in thepercentageofpe-
ripheral nerveswithOPCbodies and/or processeswhenMEPglia
and vesicular release were ablated in comparison with MEP glial
ablation alone or inhibition of neuronal activity alone (Figure 4H;
p = 0.004, TeNT versus WT; p < 0.0001, MEP glia ablated versus
MEP glia present; n = 5 larvae [uninjected], n = 7 larvae [TeNT]).
Together, these data indicate that there aremultiple, independent
mechanisms regulating OPC migration at MEP TZs.
Neuronal Activity Influences Peripheral OPC Migration
Adenosine signaling through A2a ARs is a neuromodulatory
pathway that acts to increase neurotransmitter release (CiruelaCell Reports 27, 115–128, April 2, 2019 121
Figure 5. A2a AR Inhibition Reduces Neural Activity of Spinal Cord Neurons
(A) Lateral views of a 60 hpf WT olig2:dsred;sox10:eos larva stained with an A2a AR antibody. Top: spinal cord (CNS) with A2a expression in a subset of olig2+
motor neurons (asterisks). Bottom (PNS): peripheral spinal nerves with A2a expression in motor (closed arrowheads) and sensory (open arrowheads) axons.
(B) adora2ab mRNA expression at 72 hpf in the spinal cord of a WT larva. Yellow asterisks denote motor neurons.
(C) Twenty-five hours post-fertilization olig2:egfp embryo labeled with SCH-red fluorescent antagonist. Arrowheads mark spinal cord olig2+/SCH-red+ motor
neurons.
(D) Mean ± SEM of the fold change in DF/F0 over time per individual firing event for larvae treated with DMSO (n = 8 neurons from eight larvae) and SCH-58261
(n = 11 neurons from ten larvae); p = 0.01. Scale bars, 20 mM.et al., 2006; Golder et al., 2008; Rebola et al., 2008). To confirm
that adenosine signaling through A2a ARs regulates periph-
eral OPC migration by modifying neuronal activity in the spinal
cord, we assessed the expression of the A2a AR.
In these studies, we observed A2a antibody expression at 60
and 72 hpf on peripheral motor and sensory axons, as well as
on neuronal cell bodies and axons in the spinal cord, including
olig2+ motor neurons (Figures 5A and S7A). As another method
to detect expression, we used in situ hybridization to observe
adora2ab mRNA expression. Consistent with our results using
the A2a antibody, we observed adora2ab expression in spinal
cord neurons, some of which were located in the ventral spinal
cord, where motor neurons reside (Figure 5B). We did not detect
any A2a AR or adora2ab expression on OPCs or any other glial
cells at these stages, which is consistent with published RNA
sequencing (RNA-seq) datasets that do not show adora2a
expression in mouse OPCs (Zhang et al., 2014). When we used
a fluorescently tagged SCH-58261 (SCH-red), we observed
SCH-red binding to olig2+ spinal cord motor neurons at 25 hpf122 Cell Reports 27, 115–128, April 2, 2019(Figure 5C). This expression pattern matches the previously pub-
lished expression of adora2abmRNA in spinal cord neurons and
further supports the selectivity of SCH-58261 for zebrafish A2a
ARs on neurons (Boehmler et al., 2009).
Extracellular adenosine binding to A2a ARs on neurons in-
creases firing, and in the spinal cord, A2a ARs increase motor
neuron firing (Golder et al., 2008; Patel et al., 2001; Sebasti~ao
and Ribeiro, 2015). Therefore, we hypothesized that inhibiting
A2a ARs decreased neuronal activity, which resulted in periph-
eral OPC migration. To test this hypothesis, we first tested
whether inhibiting A2a ARs decreased neuronal activity in vivo.
Using the calcium indicator GCaMP5 to detect neuronal firing,
we quantified calcium transients as a measure of neuronal activ-
ity in 72 hpf neurod:gal4;UAS:GCaMP5 larvae treated with SCH-
58261 or DMSO. Because spontaneous neuronal activity in the
spinal cord was not robust in 72 hpf larvae, we induced neuronal
firing by treating the larvae with the potassium channel blocker
4-aminopyridine 20 min prior to imaging (Ellis et al., 2012). We
then measured the change in fluorescence intensity over time
in ventral spinal cord neurons and quantified fluorescence spikes
compared with baseline. Treatment with the A2a antagonist
SCH-58261 significantly reduced neuronal firing compared
with control, such that DF/F0 values rarely rose above baseline
(Figures 5D and S7B). We conclude from this experiment
that, consistent with the effects of A2a antagonists in other spe-
cies, antagonizing A2a receptors with SCH-58261 decreases
neuronal activity in zebrafish.
Because developing zebrafish have a combination of electri-
cally and chemically coupled neurons, we also tested the effect
of inhibiting activity of electrically coupled neurons with carbe-
noxolone, a gap junction blocker (Rozental et al., 2001; Saint-
Amant and Drapeau, 2001; Solomon et al., 2003; Weber and
Ross, 2003). We treated olig2:dsred embryos from 30 hpf to
3 dpf and quantified peripheral OPCs at 3 dpf. Consistent with
our hypothesis, blocking gap junctions also resulted in signifi-
cant numbers of peripherally migrated OPCs (Figure S7C; p <
0.001, 10 mM carbenoxolone; p < 0.0001, 20 mM carbenoxolone;
n = 5–10 larvae per dose) (Saint-Amant and Drapeau, 2001).
Peripherally Migrated OPCs Rescue Myelin Deficits in
Peripheral Myelin Mutants
Our data demonstrate that A2a AR inhibition results in OPC
migration onto peripheral spinal motor nerves without otherwise
disturbing overall nerve development. This led us to hypothesize
that OPCs could be recruited onto peripheral nerves in order to
myelinate them. Previous studies from our lab demonstrate
that peripheral OPCs are capable of initiating myelination of pe-
ripheral nerves (Kucenas et al., 2009; Morris et al., 2017; Smith
et al., 2014). However, in these studies, OPCs populated the
nerve in the context of genetic mutations resulting in the death
or absence of both SCs and MEP glia. Therefore, we wanted
to determine if it was possible to recruit OPCs to myelinate pe-
ripheral motor nerves in amodel more closely resembling human
peripheral neuropathies. To do this, we used gpr126 mutant
larvae, a model in which SCs ensheath, but fail to myelinate, pe-
ripheral nerves (Monk et al., 2009). Importantly, OLs are present
in normal numbers in these mutants, and central myelination is
indistinguishable from WT larvae (Monk et al., 2009).
We first tested whether untreated gpr126 mutant larvae had
functional MEP glia. MEP glia along the spinal motor root can
be identified by expression of wif1 or by fate mapping with pho-
toconversion of the sox10:eos transgenic line (Smith et al., 2014).
Using these tools, we found that MEP glia were present on spinal
motor roots in gpr126 mutant larvae at 72 hpf (Figures 6A
and 6B). When we quantified peripheral OPC migration in
olig2:dsred;gpr126/ larvae at 3 dpf, we did not observe any
peripheral OPCs in mutants treated with DMSO (Figure 6C;
n = 8). These data demonstrate that MEP glia are present and
functioning properly and that the absence of SC myelin on pe-
ripheral nerves is not sufficient to elicit peripheral OPCmigration.
Therefore,we testedwhether treatmentwith the A2aAR antag-
onist would result in peripherally migrated OPCs. When we
treated gpr126mutant larvaewith 10mMof theA2aARantagonist
SCH-58261 from 36 hpf to 3 dpf, we observed a significant num-
ber ofolig2+OPCs in theperiphery comparedwithDMSO-treated
controls (Figure 6C; p = 0.009; n = 6). We then performed in vivo,
time-lapse imaging on nkx2.2a:megfp;olig2:dsred;gpr126/larvae inorder to visualizewhether theseperipheralOPCs initiated
myelination of peripheral motor axons (Kucenas et al., 2008a). In
larvae treated with SCH-58261 from 36 hpf to 3 dpf, we observed
nkx2.2a+/olig2+ OPCs initiate ensheathment of peripheral spinal
motor axons (Figure 6D; Video S2). These time-lapse data rule
out the possibility that SCH-58261 treatment stimulates SCs to
myelinate the nerve.
To examine whether these membrane sheaths were in fact
myelin, we treated gpr126 mutant larvae from 36 hpf to 3 dpf
with SCH-58261 or DMSO, fixed them at 4 dpf, and labeled with
an antibody specific to myelin basic protein (MBP) (Kucenas
et al., 2009). In mutant larvae treated with DMSO, we observed
MBPonlyonashortsegmentof theproximalnerve root (Figure6E),
which is consistent with our previous data showing that differenti-
ated MEP glia express MBP in this location (Smith et al., 2014). In
contrast, in mutant larvae treated with the A2a AR antagonist,
MBP labeling was present further distally along the nerve (Fig-
ure 6E). As further confirmation that peripheral OPCs myelinate
spinal motor nerve roots following treatment with SCH-58261,
we imagedmbp:egfp;olig2:dsred;gpr126/ larvae from 72 to 86
hpf (n = 3) (Figure 6F). In these time-lapses, we observed olig2+
OPCs ensheathing peripheral nerves withmbp+membrane tubes
(Video S3). Both the MBP antibody and mbp:egfp labeling were
closely associated with an olig2+ cell body, providing further
evidence that peripherally migrated OPCs, and not SCs, initiate
myelination in gpr126 mutant larvae treated with SCH-58261
(Figures 6D and 6E). From these experiments, we conclude that
OPCs can be recruited onto peripheral motor nerves and initiate
myelination, even in the presence of MEP glia and SCs.
DISCUSSION
At MEP TZs, motor axons originating within the spinal cord cross
through the glia limitans and transition into the PNS (Bonanomi
and Pfaff, 2010; Siebel et al., 2014). OPCs, in contrast, originate
within the CNS but do not cross into the periphery, despite being
highly migratory and extending membrane processes into the TZ
(Fraher and Kaar, 1984; Smith et al., 2014). The mechanisms
responsible for allowing axons and other glial populations to
cross through the MEP TZ while preventing OPCs are not fully
understood. Using selective inhibitors for AR subtypes com-
bined with genetic manipulation, we show that neuronal activity,
at least partially mediated by A2a ARs, is involved in regulating
OPC migration at the MEP TZ.
Adenosine and Activity-Dependent Regulation of OPCs
Adenosine is a ubiquitous extracellular signaling ligand in the
CNS and PNS (Abbracchio et al., 2009; Welsh and Kucenas,
2018). It can be released directly from cells into the extracellular
space through nucleoside transporters and can also be derived
from hydrolysis of extracellular ATP, which is released from syn-
aptic vesicles by most, if not all, neurons (Burnstock, 1972;
Fields and Burnstock, 2006). In the spinal cord, adenosine mod-
ulates the activity of motor neurons (Golder et al., 2008; Patel
et al., 2001). In our studies, we demonstrate that motor neurons
and interneurons within the spinal cord express A2ab receptors
and that inhibiting A2ab decreases neuronal activity. These re-
sults are consistent with data from many other model systemsCell Reports 27, 115–128, April 2, 2019 123
Figure 6. Peripheral OPCs Myelinate Spinal Motor Axons in gpr126 Mutant Larvae
(A) wif1 mRNA expression in WT and gpr126/ larvae at 3 dpf shows MEP glia (arrowheads). SC, spinal cord; N, notochord.
(B) Live images of photoconverted sox10:eos larvae at 3 dpf show Eos+ MEP glia (arrowheads) in both WT and gpr126/ larvae.
(C) Mean ± SEM of peripheral OPCs in 3 dpf gpr126/ larvae treated with DMSO or SCH-58261 from 36 hpf to 3 dpf. n = 8 DMSO, n = 6 SCH-58261. **p = 0.009.
(D) Frames from a 15 h time-lapse movie of a olig2:dsred;nkx2.2a:megfp;gpr126/ larva treated with SCH-58261 from 36 hpf to 3 dpf; 00 is 57 hpf. Arrowheads
mark a nkx2.2a+/olig2+ OPC ensheathing motor axons.
(E) Images of MBP antibody (arrowheads) on peripheral nerves of 4 dpf olig2:dsred;gpr126/ larvae treated with DMSO or SCH-58261 from 36 hpf to 3 dpf.
Asterisk marks peripheral OPC.
(F) Live images of 4 dpf WT and gpr126/;olig2:dsred;mbp:egfp larvae treated with DMSO or SCH-58261 from 36 hpf to 3 dpf. Asterisk marks olig2+ peripheral
OPC with mbp+ membrane sheaths (arrowheads) around peripheral motor axons. Scale bars, 20 mm.showing that neuronal A2a receptors act to promote activity of
spinal cordmotor neurons as well as other kinds of CNS neurons
(Sebasti~ao and Ribeiro, 2015).
The data we present fit well with growing evidence from mul-
tiple labs that neuronal activity regulates OPC and OL behaviors,
including migration, differentiation, and myelination (Almeida
and Lyons, 2017; Czopka, 2016; Gallo et al., 2008). Electrophys-
iological and in vivo time-lapse imaging studies demonstrate that
OPCs detect changes in neuronal activity or a variety of directly
applied neurotransmitters (Baraban et al., 2018; Lin and Bergles,
2004). Studies in mice and zebrafish also demonstrate that
increased neuronal activity promotes OPC differentiation and
myelination, whereas decreased activity inhibits differentiation
and leads to hypomyelination (Gibson et al., 2014; Hines et al.,124 Cell Reports 27, 115–128, April 2, 20192015; Makinodan et al., 2012; Mensch et al., 2015; Mitew
et al., 2018; Stevens et al., 2002). In addition, decreased
neuronal activity results in altered OPC distribution and migra-
tion in mouse brains (Mangin et al., 2012; Tong et al., 2009).
We hypothesize that because neuronal activity leads to OPC dif-
ferentiation, decreased activity in our experiments may affect
OPC differentiation, which could cause them to maintain their
highly migratory state. Our findings that perturbing neural activity
with SCH-58261, genetic disruption of A2ab ARs or TeNT injec-
tion leads to ectopic OPC migration, are consistent with these
studies and the hypothesis that neuronal activity regulates
OPC migration and differentiation.
Therefore, we propose a model in which A2a AR regulation of
neuronal activity participates in preventing peripheral migration
of OPCs. A2a ARs are excitatory Gs protein-coupled receptors,
which upon activation by adenosine, activate adenylyl cyclase
that in turn causes increased intracellular cyclic AMP levels
and activation of PKA (Borea et al., 2018). Through this cascade,
A2a AR activation not only modulates neuronal activity, both
pre- and post-synaptically, by increasing neurotransmitter
release and cellular excitability respectively, but also modulates
neuronal activity non-synaptically by depolarizing neurons
through the regulation of ion channels such as calcium and
potassium channels (Ribeiro and Sebasti~ao, 2010). For these
reasons, we believe that inhibiting vesicular release by tetanus
toxin and the blocking of A2a AR signaling are distinct mecha-
nisms that independently result in decreased neuronal activity,
and when disrupted together, lead to a synergistic inhibition
of neuronal activity and an enhanced phenotype of peripheral
OPCs.
Multiple Mechanisms Mediate OPC Segregation at the
MEP TZ
In a previous study, we showed thatMEP glia restrict OPCs to the
CNS by contact-mediated repulsion at MEP TZs (Smith et al.,
2014). In the present article, we demonstrate that adenosine
signaling, mediated at least partially by A2ab ARs, is another
mechanism regulating OPC restriction at the MEP TZ, indepen-
dent of MEP glial function.We provide evidence that unbalancing
neuronal activity, either by antagonizing adenosine signaling or
by blocking vesicular release or gap junctions, leads to ectopic
peripherally migrated OPCs. Our current data show that affecting
several of these mechanisms results in a cumulative phenotype
and leads to more OPCs migrating onto peripheral nerves, sug-
gesting that multiple independent mechanisms regulate OPC
migration at the MEP TZ.
This supports our hypothesis that a large range of mecha-
nisms could be compensating for the disrupted adenosine
signaling in adora2abmutant larvae and balance neuronal activ-
ity. We sought to identify the compensatory mechanisms mask-
ing the function of A2ab in OPC restriction in adora2ab mutant
larvae and hypothesized that adora2aa was compensating for
adora2ab. Surprisingly, there was no genetic compensation of
adora2ab by its paralog adora2aa. Other mechanisms, including
other ARs, could be compensating for the lack of A2ab. Eight
other ARs, encoded by eight distinct genes, including the newly
identified adora2c (Wakisaka et al., 2017), could individually or
synergistically compensate for A2ab. Because adenosine is a
neuromodulator and because genetic compensation is not
limited to genes from a same family (Rossi et al., 2015), we
also cannot rule out the possibility that other neuromodulators
and neurotransmitters could compensate for the loss of A2ab
ARs and balance neuronal activity. Glutamate signaling is an
attractive candidate, as OPCs express receptors for this neuro-
transmitter (Lin and Bergles, 2004) and motor neurons can
release glutamate in the spinal cord (Nishimaru et al., 2005). Syn-
apses between OPCs and neurons have been observed using
electron microscopy, and vesicular release of glutamate from
neurons activates AMPA and/or NMDA receptors on OPCs (Ber-
gles et al., 2000). We also acknowledge the possibility that OPCs
could respond to other factors released from neurons in an activ-
ity-dependent manner, such as ATP (Fields and Stevens, 2000).Potential for Peripheral OPCs to Myelinate Peripheral
Nerves
Our findings also offer intriguing possibilities for the treatment of
peripheral neuropathies. We and others have shown that OPCs
are capable of myelinating peripheral axons (Coulpier et al.,
2010; Kucenas et al., 2009; Morris et al., 2017; Smith et al.,
2014). However, these previous studies were in the context of
genetic mutations that result in the loss of all peripheral myelinat-
ing glia. In our studies using gpr126 mutant larvae, SCs are
present on nerves, but they fail to makemyelin, which is a feature
of some hypomyelinating peripheral myelinopathies (Monk et al.,
2011). Our data as well as previous studies in mice and zebrafish
demonstrate no peripheral OPC migration in mutants with pe-
ripheral hypomyelination, and it is unclear whether OPCs would
naturally migrate onto peripheral nerves in human neuropathy
patients (Coulpier et al., 2010; Monk et al., 2009, 2011). Because
of this, we are excited by the possibility of inducing OPCs to
migrate onto peripheral nerves that lack myelin. Once in the
periphery, our studies demonstrate that OPCs are competent
to initiate myelination without continued drug treatment. In com-
bination with previous studies, this is strong evidence for the
potential for OPCs to myelinate peripheral nerves in disease.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
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(Shin et al., 2003), Tg(nkx2.2a:megfp)vu17 (Kucenas et al., 2008b), Tg(mbp:egfp-CAAX) (Almeida et al., 2011), adora2aact845,
adora2abuva6, adora2abuva7, adora2abuva9, Tg(neuroD:gal4)uva22 and gpr126st49 (Monk et al., 2009). Table S1 denotes abbreviations
used for each strain and summarizes what each transgene labels. Embryoswere raised at 28.5C in eggwater and staged by hours or
days post fertilization (hpf and dpf, respectively). Embryos of either sex were used for all experiments (Kimmel et al., 1995). Phenyl-
thiourea (PTU) (0.004%) in egg water was used to reduce pigmentation for imaging. Stable, germline transgenic lines were used in all
experiments.
METHOD DETAILS
Chemical treatments
The LOPAC1280 library (SigmaCat. No. LO1280) was used for the chemical screen. 384well masterplates, a gift fromDrs. John Lazo
and Elizabeth Sharlow, were replated and diluted with DMSO to create 1 mM 96-well stock plates. At 24 hours post fertilization (hpf),
olig2:dsred embryos were dechorionated using 0.2%pronase. Embryos remained in pronase for 2minutes at 25Candwerewashed
4 times with egg water at 25C. One embryo was placed in each well of a 96 well plate with 198 mL of water. 2 mL of compound from
the 96 well stock plate was added to the water for a final concentration of 10 mM compound and 1%DMSO. For the initial screen, we
tested each drug once in 1 well of a 96 well plate. Each row of the plate also contained 1 positive and 1 negative control well. 4 mM
AG1478 was used as a positive control and 1%DMSOwas used as a negative control for each plate. Plates were covered with a low
evaporation lid and placed in a 28.5C incubator until analysis at 3 dpf. Plates were analyzed on a Zeiss AxioObserver inverted
microscope equipped with epifluorescence using a 10X objective (NA = 0.3). At 3 dpf, the presence or absence of peripherale2 Cell Reports 27, 115–128.e1–e5, April 2, 2019
olig2+ cells was scored for each larva. All positive hits from the primary screen were retested on 3 embryos in a secondary screen in
which LOPAC1280 compounds, AG1478, and 1% DMSO treatments were randomized across the plate and all experimenters were
blinded to the identity of compounds or controls until after analysis. Any experiment in the secondary screen in which fewer than
8 positive control embryos or greater than one DMSO treated embryo had ectopic OPCs was excluded and later repeated. For all
subsequent drug experiments, new chemical stocks were obtained from suppliers, and embryosweremanually dechorionated using
forceps. 1% DMSO was used as a negative control for all drug treatment experiments, except carbenoxolone and MK-801, which
were dissolved in distilled water. Using the same microscope and objective as in the original screen, we quantified peripheral olig2+
cells for whole larvae, excluding the first (anterior) 2 somites which are obscured by the yolk, and the last (posterior) 4 somites in the
tail, which develop more slowly than the rest of the trunk.
In vivo imaging and photoconversion
Embryos were anesthetized with 0.01% 3-aminobenzoic acid ester (Tricaine), immersed in 0.8% low-melting point agarose and
mounted laterally in glass-bottomed 35 mm Petri dishes (Electron Microscopy Sciences). After mounting, the Petri dish was filled
with egg water containing PTU and Tricaine. For some experiments, chemical compounds were also dissolved in the water.
A 25Xmulti-immersion objective (NA = 0.8), 40X oil objective (NA = 1.4) and a 40X water objective (NA = 1.1) mounted on amotorized
Zeiss AxioObserver ZI microscope equipped with a Quorum WaveFX-XI spinning disc confocal system (Quorum Technologies Inc.)
were used to capture images. Image processing was performedwithMetaMorph and Photoshop to enhance brightness and contrast
of images. The Fiji plugin MTrackJ was used to annotate time-lapse movies (Meijering et al., 2012).
We used fate mapping with photoconversion of the sox10:eos transgenic line to identify MEP glia in some experiments. The
nascent Eos protein exists in a green fluorescent state, but when exposed to ultraviolet (UV) light, it permanently shifts to a red fluo-
rescent state.When exposed toUV light at 48 hpf, neural crest-derived cells are photoconverted to red fluorescence.MEP glia, which
are not neural crest-derived and begin expressing sox10:eos after 48 hpf, are not photoconverted and can be identified as GFP+ cells
on the nerve root (Smith et al., 2014). For photoconversion, the entire trunk of sox10:eos larvae was exposed to 30 s of UV light
through a DAPI filter using a 20X objective (NA = 0.8).
Cell ablation
Single cell ablations were performed with a nitrogen-pulsed MicroPoint laser using a coumarin dye (435nm) with a 63x (MEP glia
ablation) water immersion objectives. After pre ablation images were acquired, a region of interest (ROI) was created based off
the merged-color image around MEP glia to selectively laser ablate single cells.
Calcium imaging
We injected the calcium indicator UAS:GCaMP5 DNA construct into stable transgenic zebrafish embryos neuroD:gal4. The combi-
nation of UAS:GCaMP5 and neuroD:gal4 leads tomosaic expression of GcAMP5 in CNS neurons. Prior to imaging, larvae expressing
GCaMP5 in the ventral spinal cord were treated with 800 mM 4-aminopyridine (4-AP) (Sigma A78403) diluted in egg water for
15minutes to induce neuronal activity (Ellis et al., 2012), then immediately paralyzed using the neuromuscular junction (NMJ) blocking
nicotinic receptor antagonist pancuronium bromide (Sigma P1918) for 10 minutes, which was dissolved in egg water (0.3 mg/mL)
(Baraban et al., 2018). Larvae were then embedded in 0.8% low melting point agarose for imaging. To record Ca2+ dynamics,
individual neurons of the ventral spinal cord were imaged every 250 ms for 2 minutes, using an exposure time of 100 ms on single
z-planes. Images were captured with a 63x water immersion objective (na = 1.2) mounted on a motorized Zeiss AxioObserver ZI
microscope equipped with a Quorum Wave FX-XI spinning disc confocal system (Quorum Technologies Inc.). Single-plane time-
lapses were processed in MetaMorph with no intensity averaging.
Immunohistochemistry and fluorescent antagonist treatment
Embryos were fixed and stained using the procedure previously described (Smith et al., 2014). Antibodies used were: rabbit anti-A2a
(1:100 GeneTex (Andersson et al., 2012)), rabbit anti-Sox10 (1:5000 [Binari et al., 2013]), rabbit anti-MBP (1:250 [Kucenas et al.,
2009]), and Alexa 647 goat anti-rabbit (1:600) (ThermoFisher). Fluorescent SCH-58261 (SCH-red) was purchased from CisBio. 25
hpf embryos were immersed in 7.14 mM SCH-red in 30% DMSO for 30 minutes, then fixed in 4% PFA at 25C for 3 hours. Embryos
were mounted in glass-bottomed Petri dishes for imaging as described above.
Morpholino and mRNA injections
Antisense morpholino oligonucleotides (MO) were purchased from Gene Tools. adora2aaMO1 (CATTGTTCAGCATGGTGAGG
TCGCT) (Haas et al., 2013) is complementary to the region spanning the translation start codon of adora2aamRNA, and adora2abMO1
(GTGCTATCAACCAGTGTGAAAGGAT) is complementary to the region immediately 50 to the start codon of adora2ab mRNA.
Embryos were injected with 2 to 3 nL of injection solution (distilled water, 4 mg/ml phenol red, diluted MO) at the 1-cell stage. Any
embryos damaged during the injection procedure were removed, and the rest were incubated at 28.5C. Data presented for each
MO are combined from at least 3 independent experiments. Uninjected controls and phenol red control injections were performed
at least twice for each dataset.Cell Reports 27, 115–128.e1–e5, April 2, 2019 e3
For Tetanus Toxin experiments, TeNT cDNA was prepared from plasmid pGEMTEZ-TeTxLC (a gift from Marcel Tawk) as
previously described (Fontenas et al., 2016). TeNT mRNA was prepared using the mMessage mMachine SP6 in vitro transcription
kit (ThermoFisher). Injections of mRNA encoding Tetanus Toxin Light Chain (TeNT) were performed at the one-cell stage. A 2 nL
volume of 200 ng/ml mRNA in DEPC-treated distilled water was used. All embryos were manually dechorionated at 2 dpf and
evaluated for paralysis at that time. The startle reflex was also analyzed at 3 dpf as further evidence that TeNT expression caused
inhibition of neuronal firing. For calcium imaging experiments, 2nL of 100 ng/mL UAS-GCaMP5 DNA construct diluted in injection
buffer were injected into neuroD:gal4 embryos at the one cell stage.
Creation of adora2ab mutant line
sgRNA targeting adora2ab was designed using CHOPCHOP (http://chopchop.cbu.uib.no/) and the protocol from https://www.
schierlab.fas.harvard.edu/resources/ (Gagnon et al., 2014). We annealed the 50 gene-specific oligo and the 30 constant oligo using
the PCR protocol described in Nakayama et al. (2014). We transcribed sgRNA using Ambion Megascript T7 kit and injected 2 nL of
200-400 ng/ml sgRNA with 500 ng/ml Cas9 protein (PNA Bio) dissolved in nuclease-free water into cells of olig2:dsred or olig2:egfp
embryos at the 1 cell stage. To identify founders, injected embryos were raised to adulthood and mated, then genomic DNA was
isolated from a pool of 8 embryos from each potential founder. PCR was performed using the primers CAACTATGTGTGTCCCT
GAGGA and ATGAAGAGGCATCCATGAAAAT were to amplify a 279 base pair region of genomic adora2ab, and Sanger sequencing
with the primer CAACTATGTGTGTCCCTGAGGA was used to identify CRISPR-induced indels. Sequence trace files were analyzed
with ApE or SnapGene. To identify alleles in F1 animals, we cloned single mutated DNA fragments using TOPO cloning. To analyze
the CRISPR induced-mutations, DNA from adult fin clips was extracted and amplified by PCR using the adora2ab forward (50-CAAC
TATGTGTGTCCCTGAGGA-30) and reverse (50-ATGAAGAGGCATCCATGAAAAT-30) primers. PCR was done with GoTaq green mas-
ter mix (Promega) and conditions were as follows: 95C for 3 min, followed by 35 cycles at 95C for 30 s, 60C for 30 s and 72C for
1 min. Final extension was at 72C for 20 min. PCR products from individual embryos were TOPO TA cloned into pCR8/GW or pCR4
vectors (Invitrogen). For each embryo, clones were sequenced using the M13 forward or M13 reverse primer. Sequences were
aligned to WT genomic DNA using BLAST global alignment tool. All CRISPR data presented in this manuscript was obtained using
stable, germline mutations identified in the F1 generation.
Creation of adora2aa mutant line
A TALEN targeting zebrafish adora2aa was designed using the ZiFIT Targeter (https://omictools.com/zifit-tool) (Sander et al., 2011)
and constructed as previously described (Chen et al., 2013). TALEN mRNA was synthesized from purified linear DNA using the
mMessage mMachine T7 Ultra kit (Ambion), 50-100pg of TALEN mRNA dissolved in nuclease-free water was injected into zebrafish
embryos at the 1-cell stage. To identify founders, injected embryos were raised to adulthood and mated, then genomic DNA was
isolated from a pool of 1 to 6 embryos from each potential founder. PCR was performed using the primers GTTTGTTCGAGGA
GGTGGTG and ACCACTGAGTTTGCGTGTGA, and indels were identified by analyzing PCR product sizes using Peak Scanner
(Applied Biosystems). To confirm indel sequences, genomic DNA from single embryos was amplified and subcloned using the
Strataclone PCR Cloning Kit (Stratagene), and DNA sequences were then analyzed with SeqBuilder and SeqMan (DNAStar
Lasergene).
Genotyping
Genomic DNA was extracted using HotSHOT (hot sodium hydroxide and tris) (Truett et al., 2000). The primers used for genotyping
gpr126st49 have previously been published (Monk et al., 2009). For adora2abuva6, adora2abuva7 and adora2abuva9, PCR was
performed using the primers CAACTATGTGTGTCCCTGAGGA and ATGAAGAGGCATCCATGAAAAT. For adora2abuva6 and
adora2abuva7 the mutant alleles were identified using agarose gel electrophoresis. For adora2abuva9, the WT PCR product was
digested with Tsp45i. The primers AAGCCATCCCATGTGAACTC and TCACATTCAGGGCAGAACAG were used to amplify a
151 bp product within adora2aa. Because the mutation is a 7 bp deletion and is difficult to resolve on an agarose gel, we performed
Sanger sequencing using the primer TCACATTCAGGGCAGAACAG to identify WT, heterozygous, and homozygous mutants.
In situ hybridization and sectioning
Larvae were fixed in 4% PFA at 4C overnight and stored in 100% methanol at 20C and processed for in situ RNA hybridization.
Plasmids were linearized with appropriate restriction enzymes and cRNA preparation was carried out using Roche DIG-labeling
reagents and RNA polymerases (NEB). We used previously published probes for wif1 and adora2ab (Boehmler et al., 2009; Smith
et al., 2014). After in situ hybridization, embryos were embedded in 1.5% agarose/30% sucrose and frozen in 2-methylbutane chilled
by immersion in liquid nitrogen. We collected 20 mm transverse sections on microscope slides using a cryostat microtome and
covered with 75% glycerol. For adora2ab, in situ hybridization was performed on 20 mm tissue sections. Images were obtained using
a Zeiss AxioObserver inverted microscope using a 40x oil immersion objective. All images were imported into Adobe Photoshop.
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QUANTIFICATION AND STATISTICAL ANALYSIS
GCaMP5 analysis
Fluorescence intensity measurements were extracted from ROIs using ImageJ and imported to Excel. DF/F0 were measured by
applying the following formula DF/F0 = (Ft-F0)/(F0-Fbackground), where Ft is the fluorescence intensity in the ROI in which the calcium
transient was observed at time t, F0 is the average fluorescence intensity of first three frames of the timelapse in the same ROI, and
Fbackground is the fluorescence intensity of the background at time t (Baraban et al., 2018). For each individual neuron, the average
baseline fluorescence was determined by averaging the DF/F0 of all 500 time points. For fold change quantification, all DF/F0 values
one standard deviation or more above the baseline were considered firing events, and their average was compared to the baseline.
Statistical analysis
GraphPad Prism was used for all statistical analyses. Unpaired Student’s t test or, for multiple comparisons, 1-way ANOVA followed
by Bonferonni post test, were used for quantifications of OPCs, MEP glia, Eos+ peripheral cells. 2-way ANOVA followed by Tukey’s
multiple comparison test was used for quantification of peripheral OPCs in adora2ab mutant larvae injected with TeNT, and for MEP
glial ablation combined with TeNT. Chi-square analysis was used for quantification of paralysis and startle reflex, and survival test
was used for analyzing mutant survival and hatching. A p value less than 0.05 was considered statistically significant. For dose
response experiments, 10 to 12 embryos were treated per dose, and n is reported as the range of larvae analyzed per dose.Cell Reports 27, 115–128.e1–e5, April 2, 2019 e5
